Concorde Asset Management, LLC Abb Vie Inc. Transaction History

Concorde Asset Management, LLC

$149 Million
Q1 2024

A detailed history of Concorde Asset Management, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Concorde Asset Management, LLC holds 3,070 shares of ABBV stock, worth $502,988. This represents 0.37% of its overall portfolio holdings.

Number of Shares

3,070

Previous 2,856 7.49%

Holding current value

$502,988

Previous $442,000 26.47%

% of portfolio

0.37%

Previous 0.28%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $34,201 - $38,969	214 Added 7.49%	3,070 $559,000
Q3 2023 Nov 09, 2023	SELL	$133.59 - $154.65 $2.74 Million - $3.17 Million	-20,503 Reduced 87.77%	2,856 $425,000
Q2 2023 Jul 25, 2023	SELL	$132.51 - $164.9 $837,065 - $1.04 Million	-6,317 Reduced 21.29%	23,359 $3.15 Million
Q1 2023 May 09, 2023	BUY	$144.61 - $166.54 $4 Million - $4.61 Million	27,677 Added 1384.54%	29,676 $4.73 Million
Q4 2022 Feb 02, 2023	BUY	$138.31 - $165.87 $5,809 - $6,966	42 Added 2.15%	1,999 $323,000

Q3 2022 Oct 31, 2022	BUY	$134.21 - $153.93 $262,648 - $301,241	1,957 New	1,957 $238,000
Q2 2022 Aug 05, 2022	SELL	$137.62 - $174.96 $293,405 - $373,014	-2,132 Closed	0 $0
Q1 2022 Apr 22, 2022	BUY	$131.98 - $163.75 $76,284 - $94,647	578 Added 37.19%	2,132 $317,000
Q4 2021 Feb 02, 2022	SELL	$107.43 - $135.93 $118,602 - $150,066	-1,104 Reduced 41.53%	1,554 $214,000
Q3 2021 Oct 21, 2021	BUY	$106.4 - $120.78 $67,989 - $77,178	639 Added 31.65%	2,658 $295,000
Q2 2021 Jul 20, 2021	SELL	$105.21 - $117.21 $855,462 - $953,034	-8,131 Reduced 80.11%	2,019 $230,000
Q1 2021 Apr 27, 2021	BUY	$102.3 - $112.62 $1.04 Million - $1.14 Million	10,150 New	10,150 $1.11 Million
Q3 2020 Oct 23, 2020	SELL	$85.91 - $100.83 $187,541 - $220,111	-2,183 Closed	0 $0
Q2 2020 Jul 20, 2020	BUY	$73.37 - $98.18 $160,166 - $214,326	2,183 New	2,183 $209,000
Q1 2020 Apr 22, 2020	SELL	$64.5 - $97.79 $183,696 - $278,505	-2,848 Closed	0 $0
Q4 2019 Jan 30, 2020	SELL	$72.13 - $90.25 $13,127 - $16,425	-182 Reduced 6.01%	2,848 $250,000
Q3 2019 Oct 28, 2019	SELL	$62.98 - $75.72 $45,408 - $54,594	-721 Reduced 19.22%	3,030 $239,000
Q2 2019 Aug 08, 2019	BUY	$65.7 - $83.98 $3,547 - $4,534	54 Added 1.46%	3,751 $293,000
Q1 2019 May 01, 2019	SELL	$77.14 - $90.79 $14,888 - $17,522	-193 Reduced 4.96%	3,697 $296,000
Q4 2018 Jan 25, 2019	BUY	$77.85 - $96.01 $25,924 - $31,971	333 Added 9.36%	3,890 $315,000
Q3 2018 Oct 30, 2018	BUY	$88.91 - $98.84 $70,683 - $78,577	795 Added 28.78%	3,557 $288,000
Q2 2018 Jul 17, 2018	SELL	$89.78 - $106.23 $14,275 - $16,890	-159 Reduced 5.44%	2,762 $203,000
Q1 2018 Apr 24, 2018	SELL	$92.01 - $123.21 $15,641 - $20,945	-170 Reduced 5.5%	2,921 $212,000
Q4 2017 Jan 23, 2018	BUY	$89.56 - $98.21 $447 - $491	5 Added 0.16%	3,091 $223,000
Q3 2017 Oct 31, 2017	BUY	$69.85 - $89.22 $215,557 - $275,332	3,086	3,086 $244,000

Others Institutions Holding ABBV

# of Institutions

3,653

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $290B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concorde Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Concorde Asset Management, LLC with notifications on news.

Account

Concorde Asset Management, LLC Abb Vie Inc. Transaction History